BioSpace News Archive

ValGenesis, Inc., a market leader in enterprise Validation Lifecycle Management Systems (VLMS), and ZeeDimension, a technology and quality consulting company based in Dubai, UAE, have partnered to deliver unique digital validation solutions for pharmaceutical companies in the Middle East.

AbbVie (NYSE: ABBV) will participate in the Cowen 42nd Annual Health Care Conference on Tuesday, March 8, 2021.

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a panel discussion and one-on-one investor meetings at Cowen’s 42nd Annual Healthcare Conference.

DURECT Corporation (Nasdaq: DRRX) today announced it dosed the first patient in the European Union as part of its AHFIRM randomized, double-blind, placebo-controlled, multi-center Phase 2b study to evaluate the safety and efficacy of larsucosterol in severe alcohol-associated hepatitis (AH) patients.

Screen Therapeutics LLC, today announced preliminary, preclinical findings highlighting the potential of modulating extracellular matrix (ECM) associated proteins.

Moleculin Biotech, Inc. today announced the appointment of Joy Yan, M.D., Ph.D. to its Board of Directors.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the New Drug Application (NDA) for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor under review for the treatment of HIV-1 infection in heavily treatment-experienced (HTE) people with multi-drug resistant (MDR) HIV-1 infection.

Stevanato Group announced that its subsidiary, OMPI of America Inc., entered into an agreement to support the Biomedical Advanced Research and Development Authority pursuant to which BARDA has agreed to provide up to approximately $95 million to Stevanato Group.

Jaguar Health, Inc. announced that the company is hosting a treatment forum for veterinarians about chemotherapy-induced diarrhea in dogs at the Mandalay Bay Resort and Casino in Las Vegas on Sunday, March 6, 2022 from 5:30 PM - 7:30 PM Pacific Time during the Western Veterinary Conference, which is being held at the same location.

Bold Therapeutics, a clinical-stage biopharmaceutical company, announced that they have successfully completed the Phase 1b (dose-escalation) portion of its seamless adaptive oncology trial of BOLD-100 in combination with FOLFOX in the treatment of advanced gastrointestinal cancers (colorectal, pancreatic, gastric and bile duct).